ITMI20041772A1 - Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione. - Google Patents

Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Info

Publication number
ITMI20041772A1
ITMI20041772A1 IT001772A ITMI20041772A ITMI20041772A1 IT MI20041772 A1 ITMI20041772 A1 IT MI20041772A1 IT 001772 A IT001772 A IT 001772A IT MI20041772 A ITMI20041772 A IT MI20041772A IT MI20041772 A1 ITMI20041772 A1 IT MI20041772A1
Authority
IT
Italy
Prior art keywords
thiamine
learning
defects
treatment
pathologies linked
Prior art date
Application number
IT001772A
Other languages
English (en)
Inventor
Michele Bonanomi
Bruno Silvestrini
Original Assignee
Bioprogress Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprogress Spa filed Critical Bioprogress Spa
Priority to IT001772A priority Critical patent/ITMI20041772A1/it
Publication of ITMI20041772A1 publication Critical patent/ITMI20041772A1/it
Priority to US11/663,131 priority patent/US20080311200A1/en
Priority to EP05733449A priority patent/EP1811972A1/en
Priority to CA002580330A priority patent/CA2580330A1/en
Priority to PCT/IB2005/001206 priority patent/WO2006030260A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IT001772A 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione. ITMI20041772A1 (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.
US11/663,131 US20080311200A1 (en) 2004-09-17 2005-05-02 Controlled Slow Release Formulation of Thiamine and Use Thereof in the Treatment of Pathologies Connected to Defective Process of Learning and Memorization
EP05733449A EP1811972A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization
CA002580330A CA2580330A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization
PCT/IB2005/001206 WO2006030260A1 (en) 2004-09-17 2005-05-02 A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorization

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Publications (1)

Publication Number Publication Date
ITMI20041772A1 true ITMI20041772A1 (it) 2004-12-17

Family

ID=34968626

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001772A ITMI20041772A1 (it) 2004-09-17 2004-09-17 Formulazione a rilascio controllato di tiamina e loro impiego nel trattamento di patologie collegate a difetti nei processi di apprendimento e memorizzazione.

Country Status (5)

Country Link
US (1) US20080311200A1 (it)
EP (1) EP1811972A1 (it)
CA (1) CA2580330A1 (it)
IT (1) ITMI20041772A1 (it)
WO (1) WO2006030260A1 (it)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
JPS61151133A (ja) * 1984-12-25 1986-07-09 Toyo Jozo Co Ltd 遅延放出性被覆組成物及びこれにより被覆した被覆製剤
JPS63222112A (ja) * 1987-03-10 1988-09-16 Nippon Soda Co Ltd 徐放性顆粒
JPH01308232A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 固型医薬およびその製造法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
AU646840B2 (en) * 1990-02-05 1994-03-10 Board Of Regents, The University Of Texas System Dietary supplements comprising vitamins and minerals
US5167964A (en) * 1992-02-14 1992-12-01 Warner-Lambert Company Semi-enteric drug delivery systems and methods for preparing same
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US6352713B1 (en) * 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US5869084A (en) * 1994-06-20 1999-02-09 K-V Pharmaceuticals Co. Multi-vitamin and mineral supplements for women
US6488956B1 (en) * 1994-06-20 2002-12-03 Drugtech Corporation Multi-vitamin and mineral supplements for women
US5843469A (en) * 1997-04-11 1998-12-01 Mcentee; William J. Lipid soluble forms of thiamine for prevention and treatment of age-related cognitive impairment of the nervous system
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US20040259895A1 (en) * 1998-05-28 2004-12-23 Medical Research Institute Oral formulation of lipid soluble thiamine and lipoic acid
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6245360B1 (en) * 1998-06-26 2001-06-12 John S. Markowitz Nutritional supplement

Also Published As

Publication number Publication date
US20080311200A1 (en) 2008-12-18
WO2006030260A1 (en) 2006-03-23
CA2580330A1 (en) 2006-03-23
EP1811972A1 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
HUS1800041I1 (hu) Piperazinnal helyettesített benzotiofének mentális rendellenességek kezelésére
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
CR10699A (es) Antagonistas de wnt y su uso en el diagnostico y tratamiento de trastornos mediados por wnt
LU93081I2 (fr) Ambrisentan utilisé en traitement combiné avec tadalafil
DE602007004842D1 (de) Vorrichtung zur Unterstützung bei der Herzbehandlung
EP1922637A4 (en) FORMATION OF NEURAL FOLDING NETWORKS ON GRAPHICS PROCESSING UNITS
BRPI0718429A2 (pt) Suspensões aquosas farmacêuticas contendo o rebamipide e processo para a fabricação das mesmas
DE602006012666D1 (de) Ren eignen und verfahren zu deren herstellung
EP1989632A4 (en) METHOD AND APPARATUS FOR DELETING DEFORMATIONS BASED ON A MODEL
JP2009039101A5 (it)
SI3095447T1 (sl) Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
DK1919450T3 (da) Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
SI2432798T1 (sl) Derivat 17-hidroksi-17-pentafluoretil-estra-4,9(10)-dien-11-arila, postopki izdelave in uporaba pri zdravljenju bolezni
EP1788050A4 (en) AQUEOUS PRESERVATION COMPOSITION, SURFACE TREATMENT METHOD USING THE SAME AND MULTILAYER STRUCTURE
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
EP1835919A4 (en) TREATING DRY EYES
NO20070892L (no) Sammensetninger av N-glykolylneuraminsyre og anvendelse derav ved behandling av forkjølelse.
BRPI0817483A2 (pt) uso de n-fenilamidas de ácido 2-sulfonilaminobenzoico substituídas por sulfonila no tratamento da dor
EP1930385A4 (en) AQUEOUS SURFACE TREATMENT AND SURFACE TREATED CONSTRUCTION
EP1902406A4 (en) BIOMETRIC DRUG CONTAINER
FI20050225A0 (fi) Primerointi- ja päällystysprosessi
DE112006003255A5 (de) Walzenbürste und ihre Herstellungsverfahren
DE602005000013D1 (de) Doppelschichtkondensator und Elektrolytlösung dafür
DE502006006768D1 (de) MIM-Kondensator sowie zugehöriges Herstellungsverfahren
FR2895412B1 (fr) Procede de preparation de nanoparticules en feuillets et nanoparticules obtenues.